In a report recently released in collaboration with Roche Canada, the Ontario Chamber of Commerce (OCC) urged the federal and provincial governments, the life sciences industry, and the research community to prioritize positioning Canada as a prime destination for clinical trials.
As further priorities, the policy report also recommended helping patients access new treatments sooner and treating connected health data as economic infrastructure.
The report suggested:
- reducing start-up times by streamlining approvals, improving incentives, and pursuing a coordinated “National One Stop Shop” model
- updating regulatory and reimbursement pathways and scaling successful approaches, including Ontario’s Funding Accelerated for Specific Treatments (FAST) pilot
- establishing interoperable health data systems for improved care, research, and investment
In its media release, the OCC claimed that a connected health information system, if fully optimized, could represent nearly $10 billion in value for the country every year.
Challenges faced by patients and health professionals
The policy report identified the following issues within the life sciences sector:
- slow clinical trials
- lengthy waiting periods, with Canadians waiting an estimated 52 months from a medicine’s first global launch to public reimbursement
- disconnected health data
“Faster trials, quicker access to medicines and connected health data can drive investment, skilled jobs and new treatments here at home,” said Daniel Tisch, the OCC’s president and chief executive officer, in the media release.
Report’s objectives
According to the OCC, the policy report aims to assist in tackling these issues, drawing in investment and generating job opportunities within the life sciences sector, and establishing Canada as a leader in the global life sciences race.
The OCC explained that Canada’s share of clinical trials worldwide has dropped to about four percent this year from six percent in 2021, representing approximately $2.5 billion in foregone research spending and 20,000 jobs.
More on Canada’s life sciences sector
According to the OCC’s media release, within the country’s life sciences sector, over 220,000 individuals are working across around 3,800 companies, with more than 101,000 direct jobs in Ontario.
The OCC acknowledged:
- Ontario’s Life Sciences Strategy
- Canada’s recently established Pharmaceutical and Life Sciences Sector Task Force
- the national security strategy’s designation of pharmaceuticals and biotechnology as a key strategic capability
However, the OCC emphasized the continuing barriers that would limit the impacts of those investments.
“The life sciences sector advances health and fuels economic growth, but to unlock its full potential, we must actively value its contributions and incentivize ongoing innovation,” said Laura Pagnotta, Roche Canada’s vice president, external affairs.
More news on health sciences
Last June 30, the Digital Governance Standards Institute (DGSI) announced a new exploratory initiative, including a public consultation, to develop a proposed national standard of Canada for patient-controlled, verifiable health records and healthcare encounter receipts.
On June 2, the DGSI shared that it was working to develop a new standard, the Data Governance Framework for Healthcare Organizations, to promote trust, privacy, and accountability in healthcare data.
Enjoy this story? Read the latest health science news on the main page!

